Brokerages expect Intrexon (NYSE:XON) to post ($0.24) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Intrexon’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.22). Intrexon reported earnings of ($0.26) per share in the same quarter last year, which would suggest a positive year over year growth rate of 7.7%. The business is scheduled to announce its next earnings results on Wednesday, May 9th.
On average, analysts expect that Intrexon will report full-year earnings of ($0.92) per share for the current fiscal year, with EPS estimates ranging from ($1.12) to ($0.47). For the next fiscal year, analysts expect that the company will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.75) to ($0.23). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Intrexon.
Intrexon (NYSE:XON) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.08. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The business had revenue of $77.03 million for the quarter, compared to analyst estimates of $48.16 million. During the same quarter in the previous year, the business earned ($0.37) earnings per share. The firm’s revenue was up 67.5% compared to the same quarter last year.
A number of research firms have recently issued reports on XON. Bank of America cut their price target on shares of Intrexon from $21.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, March 2nd. Northland Securities restated a “buy” rating and set a $17.00 price target on shares of Intrexon in a report on Friday, March 2nd. JPMorgan Chase restated a “neutral” rating and set a $18.00 price target (down previously from $22.00) on shares of Intrexon in a report on Monday, March 5th. Zacks Investment Research upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. Finally, ValuEngine lowered shares of Intrexon from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. Intrexon presently has an average rating of “Hold” and a consensus target price of $34.67.
XON stock opened at $19.62 on Monday. Intrexon has a 52-week low of $10.26 and a 52-week high of $26.99. The company has a current ratio of 1.92, a quick ratio of 1.67 and a debt-to-equity ratio of 0.01. The company has a market cap of $2,564.54, a PE ratio of -21.33 and a beta of 1.11.
In related news, CEO Randal J. Kirk acquired 1,000,000 shares of the company’s stock in a transaction on Friday, January 19th. The shares were purchased at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 55.10% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in XON. Bank of New York Mellon Corp increased its stake in Intrexon by 1.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 237,373 shares of the biotechnology company’s stock valued at $4,512,000 after buying an additional 3,234 shares during the period. SG Americas Securities LLC acquired a new position in Intrexon in the 3rd quarter valued at approximately $139,000. JPMorgan Chase & Co. increased its stake in Intrexon by 7,504.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 59,622 shares of the biotechnology company’s stock valued at $1,122,000 after buying an additional 58,838 shares during the period. Wells Fargo & Company MN increased its stake in Intrexon by 13.8% in the 3rd quarter. Wells Fargo & Company MN now owns 118,462 shares of the biotechnology company’s stock valued at $2,252,000 after buying an additional 14,333 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Intrexon in the 3rd quarter valued at approximately $1,945,000. Hedge funds and other institutional investors own 75.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “-$0.24 Earnings Per Share Expected for Intrexon (XON) This Quarter” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/16/0-24-earnings-per-share-expected-for-intrexon-xon-this-quarter.html.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Get a free copy of the Zacks research report on Intrexon (XON)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.